Can we improve the classification of ampullary adenocarcinoma? The value of histomolecular classification and clinicopathological features on prognosis - 24/09/21

Doi : 10.1016/j.soda.2021.100023 
Paula Muñoz-Muñoz 1, , Irene Carretero 2 , Raquel Arranz 1 , Esther Moreno 2 , Laura Del Campo Abendea 3 , Ángela Santana 1, Cristian Perna 2 , Alejandra Caminoa 2 , Javier Zamora 3 , José María Fernandez Cebrián 4, Alfonso Sanjuanbenito 1
1 Hospital Universitario Ramón y Cajal, General and Digestive Surgery, Madrid 
2 Hospital Universitario Ramón y Cajal, Pathology, Madrid 
3 Hospital Universitario Ramón y Cajal, Biostatistics, Madrid 
4 Hospital Universitario Ramón y Cajal, Chief of department. General and Digestive Surgery, Madrid 

Correspondence Author: Paula Muñoz Muñoz, Postal: C/Pez 16 4B, 28004, MadridPostal: C/Pez 16 4BMadrid28004
En prensa. Manuscrito Aceptado. Disponible en línea desde el Friday 24 September 2021
This article has been published in an issue click here to access

HIGHLIGHS

The prognostic implications of the histomolecular classification are yet to be stablished with large and multicentric studies
Our study underline the lack of congruence of the classical histological classification, showing a Kappa agreement index of 0.59, which means that 25% of the cases were re-classified.
The histomolecular classification used in this study modified the AA subtype (PB vs INT) in 32% of the cases
The best histomolecular classification and the combination of molecular markers that better categorize AA is yet to be stablished
Histomolecular classification using IHQ methods could improve CT selection in an heterogenous disease as AA. 37.5% of our patients would have been treated with an inappropriate regimen for their cell line when re-classified with the histomolecular classification.

El texto completo de este artículo está disponible en PDF.

ABSTRACT

BACKGROUND

Ampullary adenocarcinoma (AA) can originate from three different epitheliums, conditioning its evolution and prognosis. Recently, histomolecular classification has been defined, according to the presence of immunohistochemical (IHQ) markers of intestinal (INT) lineage vs pancreatobiliary (PB).

METHODS

42 AA patients were retrospectively reviewed and morphologically and molecular classified with IHQ MUC1, MUC2, CDX2, CK20 and CK7 markers, according to the system described by Chang et al. A prognostic study was carried out in relation to histological and histomolecular characterization and other clinicopathological variables.

RESULTS

24 patients (57%) were pancreatobiliary (Chang-PB) and 16 (43%) intestinal (Chang-INT), 2 patients could not be classified. The histological classification (post-surgical report vs reviewed) showed a congruence of 75% with a kappa concordance index of 0.595. The Chang-PB molecular classification showed lower survival in all comparisons, but it was not statistically significant (long-rank> 0.05). Univariable analysis showed that only lymph node invasion and CK20 staining were associated with overall survival.

CONCLUSION

An IHC classification could improve the prognostic characterization of AA, however, there is a lack of evidence on the clinical importance of molecular markers in AA with conflicting results, and its applicability has yet to be established.

El texto completo de este artículo está disponible en PDF.

KEYWORDS : ampullary adenocarcinoma, MUC1, CDX2, histomolecular phenotype, immunohistochemical typing


Esquema


 Conflicts of Interest and Source of Funding: None declared
 Declaration of interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.


© 2021  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.